Dendreon Announces Webcast Presentation at J.P. Morgan Healthcare Conference
SEATTLE--(BUSINESS WIRE)-- Dendreon Corporation (DNDN) today announced that management will present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2012, at 3:30 p.m. PT.
The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreons first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.
Katherine Stueland, 206-829-1522
Vice President, Corporate Communications and Investor Relations
Source: Dendreon CorporationCopyright Business Wire 2012